Wegovy pill demonstrated greater weight loss than orforglipron

2 April 2026

In a further development in the rivalry between Novo Nordisk (NOV: N) and Eli Lilly (NYSE; LLY) in the obesity space, the Danish pharma major today said it will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy (semaglutide) tablets 25mg was associated with significantly greater mean weight loss than orforglipron 36mg in a population-adjusted indirect treatment comparison.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Pharmaceutical

Following FDA nod, Novo Nordisk expects to launch Wegovy HD in the USA in April

20 March 2026

Pharmaceutical

FDA fast-tracks Lilly’s oral GLP-1 Foundayo in landmark approval

2 April 2026

Pharmaceutical

Novo Nordisk, TUL advance triple agonist after Phase II data

25 March 2026

Company News Directory

Companies featured in this story

More ones to watch >

Company Spotlight

Neurizon Therapeutics

A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.